Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.…
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Pliant Therapeutics (NASDAQ: PLRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 49 employees.
The shares were at 0.5951 USD on 20 November 2026, down 61.1% over 52 weeks. Its 52-week range is 0.5719 USD to 1.815 USD: the price is 67.2% below the high and 4.1% above the low.
Its market capitalisation is 36.89M USD.
Pliant Therapeutics reports return on equity of -82.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 129.36M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Hold; their mean price target of 2.000 USD is 236.1% above the current price. The next earnings report is expected on 17 March 2027.